glp 1 and sarcopenia GLP-1-derived therapies sarcopenia: plea for a specific focus on at risk special populations While GLP-1 medications are effective – The role of glucagon-like peptides

n=8), GH (3.5 mg/kg per day

Stomach acid and pepsin are required to free food-bound B12, which then binds to salivary R-proteins

Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment

Supports joint cartilage and bone density

Its becoming a multi-disease cardiometabolic platform spanning: Cardiovascular disease Obstructive sleep apnoea (OSA) MASH Chronic kidney disease And importantly: Oral obesity therapy is now real not theoretical But the category is already splitting: Peptide oral (with friction) Small-molecule oral (lower friction) That distinction will matter more than pill vs injection Peptide oral (with friction) Small-molecule oral (lower friction) That distinction will matter more than pill vs injection The Most Misunderstood Opportunity: OSA OSA has gone from interesting to commercially meaningful fast Tirzepatide is now the first approved drug for OSA in obesity Phase 3 data showed:~2529 events/hour reduction in AHI Up to ~50% reaching disease-resolution criteria Thats real